Literature DB >> 9864771

[Detection of cancer, sensitivity of the test and sensitivity of the screening program].

G Launoy1, S W Duffy, T C Prevost, V Bouvier.   

Abstract

In assessment of screening for cancer, no distinction is usually made between the sensitivity of the screening test (St) and the sensitivity of the screening program (Sp). This paper was aimed to distinguish meaning, method for assessment and interest for each of them, and to determine their relationship. Sensitivity of the screening program can be directly assessed with data from on-going trials whilst assessment of sensitivity of screening test requires modelisation techniques, especially for assessing the mean duration of the preclinical phase of cancer. Assuming an exponential distribution of this duration, lambda as the time parameter, a mathematical relation between St and Sp is suggested as follows: [formula: see text] with r being the interval between two screening tests. The implementation of this equation with data from a mass-screening program for colorectal cancer in the department of Calvados allowed us to investigate the influence of the mean preclinical phase and the interval between two screening tests on the value of the sensitivity of the screening procedure. Such a modelisation could be useful in the development of a rational screening policy.

Entities:  

Mesh:

Year:  1998        PMID: 9864771

Source DB:  PubMed          Journal:  Rev Epidemiol Sante Publique        ISSN: 0398-7620            Impact factor:   1.019


  9 in total

1.  Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence.

Authors:  Nora Pashayan; Paul Pharoah; László Tabár; David E Neal; Richard M Martin; Jenny Donovan; Freddie Hamdy; Stephen W Duffy
Journal:  Cancer Epidemiol       Date:  2010-08-16       Impact factor: 2.984

2.  Polygenic susceptibility to prostate and breast cancer: implications for personalised screening.

Authors:  N Pashayan; S W Duffy; S Chowdhury; T Dent; H Burton; D E Neal; D F Easton; R Eeles; P Pharoah
Journal:  Br J Cancer       Date:  2011-04-05       Impact factor: 7.640

3.  Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.

Authors:  Stephen Duffy; Daniel Vulkan; Howard Cuckle; Dharmishta Parmar; Shama Sheikh; Robert Smith; Andrew Evans; Oleg Blyuss; Louise Johns; Ian Ellis; Peter Sasieni; Chris Wale; Jonathan Myles; Sue Moss
Journal:  Health Technol Assess       Date:  2020-10       Impact factor: 4.014

4.  What should the detection rates of cancers be in breast screening programmes?

Authors:  S W Duffy; R Gabe
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

5.  Predictors of adherence to repeat fecal occult blood test in a population-based colorectal cancer screening program.

Authors:  C Pornet; B Denis; P Perrin; I Gendre; G Launoy
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

6.  Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening.

Authors:  Manon van der Vlugt; Esmée J Grobbee; Patrick Mm Bossuyt; Evelien Bongers; Wolfert Spijker; Ernst J Kuipers; Iris Lansdorp-Vogelaar; Marie-Louise Essink-Bot; Manon C W Spaander; Evelien Dekker
Journal:  Br J Cancer       Date:  2016-12-06       Impact factor: 7.640

7.  Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.

Authors:  N Pashayan; S W Duffy; P Pharoah; D Greenberg; J Donovan; R M Martin; F Hamdy; D E Neal
Journal:  Br J Cancer       Date:  2009-03-17       Impact factor: 7.640

8.  Translation of research results to simple estimates of the likely effect of a lung cancer screening programme in the United Kingdom.

Authors:  S W Duffy; J K Field; P C Allgood; A Seigneurin
Journal:  Br J Cancer       Date:  2014-02-13       Impact factor: 7.640

9.  Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme.

Authors:  Dimitrios Michalopoulos; Stephen W Duffy
Journal:  J Med Screen       Date:  2016-03-02       Impact factor: 2.136

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.